31,873 Tempus AI, Inc. $TEM Shares Acquired by Washington Trust Advisors Inc.

Washington Trust Advisors Inc. lifted its holdings in Tempus AI, Inc. (NASDAQ:TEM) by 35.7% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 121,039 shares of the company’s stock after acquiring an additional 31,873 shares during the quarter. Washington Trust Advisors Inc.’s holdings in Tempus AI were worth $9,913,000 as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in TEM. Guardian Partners Inc. lifted its position in Tempus AI by 8.3% during the third quarter. Guardian Partners Inc. now owns 2,600 shares of the company’s stock valued at $213,000 after purchasing an additional 200 shares during the period. V Square Quantitative Management LLC acquired a new stake in Tempus AI during the 3rd quarter worth about $27,000. Cyndeo Wealth Partners LLC grew its position in Tempus AI by 6.7% during the 3rd quarter. Cyndeo Wealth Partners LLC now owns 6,412 shares of the company’s stock worth $525,000 after purchasing an additional 400 shares during the period. Arkadios Wealth Advisors raised its stake in shares of Tempus AI by 9.6% during the 1st quarter. Arkadios Wealth Advisors now owns 4,963 shares of the company’s stock valued at $224,000 after buying an additional 435 shares during the last quarter. Finally, GAMMA Investing LLC raised its stake in shares of Tempus AI by 54.3% during the 3rd quarter. GAMMA Investing LLC now owns 1,239 shares of the company’s stock valued at $101,000 after buying an additional 436 shares during the last quarter. Hedge funds and other institutional investors own 24.22% of the company’s stock.

Tempus AI Stock Performance

TEM traded up $3.80 on Friday, reaching $67.61. The stock had a trading volume of 4,678,111 shares, compared to its average volume of 6,570,224. Tempus AI, Inc. has a 12-month low of $40.77 and a 12-month high of $93.38. The company has a current ratio of 3.30, a quick ratio of 3.16 and a debt-to-equity ratio of 3.06. The business’s 50-day moving average price is $69.24 and its two-hundred day moving average price is $57.19. The company has a market cap of $12.20 billion, a P/E ratio of -46.95 and a beta of 3.54.

Tempus AI (NASDAQ:TEM) last issued its quarterly earnings data on Thursday, July 30th. The company reported ($0.04) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.14) by $0.10. Tempus AI had a negative net margin of 17.77% and a negative return on equity of 50.28%. The business had revenue of $382.49 million during the quarter, compared to the consensus estimate of $379.69 million. During the same quarter in the prior year, the firm posted ($0.22) earnings per share. The company’s revenue was up 21.6% compared to the same quarter last year. Sell-side analysts forecast that Tempus AI, Inc. will post -1.43 earnings per share for the current year.

Wall Street Analysts Forecast Growth

TEM has been the subject of several analyst reports. Rothschild & Co Redburn initiated coverage on Tempus AI in a report on Tuesday, September 8th. They issued a “neutral” rating and a $67.00 price objective for the company. JPMorgan Chase & Co. raised their target price on Tempus AI from $45.00 to $70.00 and gave the stock a “neutral” rating in a report on Wednesday, October 14th. BTIG Research lifted their price target on Tempus AI from $70.00 to $80.00 and gave the company a “buy” rating in a research report on Thursday, August 20th. Stifel Nicolaus decreased their price target on Tempus AI from $60.00 to $50.00 and set a “hold” rating for the company in a report on Monday, August 3rd. Finally, Raymond James Financial set a $80.00 price target on Tempus AI in a report on Wednesday, September 2nd. Eleven equities research analysts have rated the stock with a Buy rating, nine have issued a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $72.37.

Tempus AI News Summary

Here are the key news stories impacting Tempus AI this week:

• Positive Sentiment: Needham reiterates Buy rating: Needham & Company maintained its Buy recommendation and set a $75 price target, implying roughly 11% upside from the cited share price. The call reinforces Wall Street support for Tempus’ growth outlook. Needham analyst recommendations
• Positive Sentiment: Expanded Bristol Myers Squibb relationship: Tempus announced multi-year oncology and AI-data agreements with Bristol Myers Squibb, a major pharmaceutical validation of its clinical-data platform. The collaboration could support recurring data-related revenue and increase Tempus’ role in drug development. Tempus expands Bristol Myers partnership
• Positive Sentiment: New Pathos AI partnership expands neuroscience reach: Tempus is partnering with Pathos AI and Bristol Myers Squibb on medical research, including neurology and neuroscience applications. Pathos’ $237 million financing and approximately $3 billion valuation may increase the visibility and perceived strategic value of Tempus’ data and AI capabilities. Tempus expands neurology data partnership
• Positive Sentiment: Investor commentary remains constructive: Recent analyses describe Tempus as less risky than previously viewed and highlight its proprietary healthcare-data advantage, as well as its involvement with Moderna’s cancer-vaccine efforts. These opinions add momentum, although they are not company financial results. Tempus AI less risky analysis
• Neutral Sentiment: Tempus remains unprofitable and carries elevated volatility, so investors will likely focus on whether these partnerships translate into sustained revenue growth and improved margins. The company’s recent quarterly results showed stronger-than-expected revenue and a narrower-than-expected loss, but execution remains important.

Insiders Place Their Bets

In related news, CEO Ryan Fukushima sold 41,095 shares of Tempus AI stock in a transaction dated Tuesday, August 18th. The stock was sold at an average price of $49.61, for a total value of $2,038,722.95. Following the completion of the transaction, the chief executive officer owned 562,463 shares in the company, valued at $27,903,789.43. The trade was a 6.81% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, EVP Andrew Polovin sold 22,148 shares of the company’s stock in a transaction dated Tuesday, August 18th. The stock was sold at an average price of $49.61, for a total value of $1,098,762.28. Following the completion of the transaction, the executive vice president directly owned 146,067 shares of the company’s stock, valued at $7,246,383.87. The trade was a 13.17% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 1,280,965 shares of company stock worth $80,397,564 in the last 90 days. 24.26% of the stock is currently owned by company insiders.

Tempus AI Company Profile

Tempus AI, Inc is a healthcare technology company that uses artificial intelligence and data analytics to support precision medicine. The company combines clinical, molecular and imaging data to help physicians make more informed treatment decisions and to help researchers and biopharmaceutical companies develop therapies.

Its offerings include genomic testing and analysis, such as tissue- and blood-based tests, as well as software tools designed to assist with clinical decision-making, patient matching for clinical trials and the management of healthcare data.